期刊
BRITISH JOURNAL OF CANCER
卷 96, 期 1, 页码 16-20出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6603520
关键词
papillary thyroid cancer; RET/PTC oncogene; RAS
类别
资金
- NCI NIH HHS [R01 CA102572-02, R21 CA111461, R01 CA102572, R21 CA111461-01] Funding Source: Medline
Activating mutations in the gene encoding BRAF are the most commonly identified oncogenic abnormalities in papillary thyroid cancer. In vitro and in vivo models have demonstrated that overexpression of activated BRAF induces malignant transformation and aggressive tumour behaviour. BRAF and other RAF kinases are frequently activated by other thyroid oncogenes and are important mediators of their biological effects including dedifferentiation and proliferation. Because current therapeutic options for patients with thyroid cancers that are aggressive and/or do not respond to standard therapies are limited, BRAF and its downstream effectors represent attractive therapeutic targets. In this review, data supporting a role for BRAF activation in thyroid cancer development and establishing the potential therapeutic efficacy of BRAF-targeted agents in patients with thyroid cancer will be reviewed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据